Metastatic clear cell renal cell carcinoma MedDRA version: 7 Level: PT Classification code 10038415
Conditions
Sponsors
F. Hoffmann-La Roche Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Signed written informed consent (approved by the Institutional Review Board [IRB]/Independent Ethics Committee [IEC]) obtained prior to any study specific screening procedures. 2. Patient must be willing and able to comply with the protocol. 3. Age 18 or over. 4. Patient was nephrectomised for primary renal cell carcinoma (clear cell type). 5. Patient with renal cell carcinoma (RCC) for whom a component of conventional clear cell type is mandatory. (Patient with true papillary, sarcomatoid features without any clear cell component, chromophobe, oncocytoma, collecting duct tumours, Bellini tumours and transitional cell carcinoma are not allowed.) If the initial diagnosis (of RCC) is dated more then 2 years ago, histological confirmation of renal cell carcinoma (clear cell type) origin of the current lesions is mandatory. 6. Females with a negative pregnancy test (within 7 days before treatment start) unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating. 7. Fertile women ( 1.5 x 109/L, Platelet count > 100 x 109/L, Haemoglobin > 9 g/dL (may be obtained or exceeded by the use of erythropoietin, excluding transfusion for anaemia), International Normalized Ratio (INR) =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Prior treatment for metastatic RCC disease (including neo-adjuvant therapy). 2. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study. 3. Serious non-healing wound, ulcer or bone fracture. 4. Evidence of current central nervous system (CNS) metastases or spinal cord compression. If clinically indicated, patient must undergo a MRI or CT scan of the brain (with contrast, if possible) within 28 days prior to randomisation. 5. Seizure(s) not controlled with standard medical therapy. 6. Other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix). 7. Evidence of bleeding diathesis or coagulopathy. 8. Ongoing or recent (within 10 days prior to study treatment start) need for full therapeutic dose of oral or parenteral anticoagulants or chronic daily treatment with aspirin (> 325 mg/day). 9. Uncontrolled hypertension (greater than or equal to 160 mm Hg systolic and/or greater than or equal to 90 mm Hg diastolic) while receiving chronic medication. 10. Clinically significant (i.e. active) cardiovascular disease, for example cerebrovascular accidents (= 6 months), myocardial infarction (= 6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication. 11. Recent (within the 30 days prior to randomisation) treatment with another investigational drug or participation in another investigational study. 12. Chronic treatment with corticosteroids (dose of = 10 mg/day methylprednisolone equivalent), excluding inhaled steroids. 13. History or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: •To determine the efficacy of the combination of bevacizumab and interferon alfa-2a as compared with interferon alfa-2a and placebo in patients with metastatic RCC, based on overall survival. Secondary objectives ;Secondary Objective: •To determine the progression free survival, time to disease progression, time to treatment failure and objective response rates of bevacizumab and interferon alfa-2a as compared with interferon alfa-2a and placebo. •To characterize the safety profile of the combination of bevacizumab and interferon alfa-2a as compared with interferon alfa-2a and placebo. •To explore the potential existence of anti-bevacizumab antibodies. ;Primary end point(s): Analysis of overall survival will be performed after approximately 445 deaths have been observed. | — |
Countries
Czech Republic, Italy, United Kingdom
Outcome results
None listed